VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2021 | Tazemetostat and rituximab in r/r follicular lymphoma

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, comments on preliminary findings from a Phase II single-arm, open-label trial (NCT04762160) of tazemetostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, with rituximab in patients with relapsed/refractory follicular lymphoma (FL). Five patients have been enrolled so far and tazemetostat with rituximab have shown initial promise in patients, with further data yet to be published. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter